甲胺和雌激素调节在LABC与T2DM:一个36个月的随机试验
Fengjia Liu1, Chunhong Xu1, Yingcheng Bai1
1No. 971 Hospital of the People's Liberation Army Navy, Qingdao, Shandong, 266000, China.
Open medicine (Warsaw, Poland)
|October 13, 2025
概括
在患有局部晚期乳腺癌和2型糖尿病的患者中,甲福明显著改善了雌激素控制和代谢稳定性. 这种综合方法提高了生存结果,并支持其用于管理复杂的并发症.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 局部晚期乳腺癌 (LABC) 和2型糖尿病 (T2DM) 存在复杂的挑战,包括激素驱动的进展和代谢失调.
- 梅特福林的潜在抗瘤效应已得到认可,但其对雌激素调节的影响和与LABCT2DM患者的护理协同需要临床研究.
研究的目的:
- 评估甲胺对LABC和T2DM患者雌激素调节的影响.
- 评估甲胺对该患者群体的预后相关护理结果的影响,包括代谢控制和存活率.
主要方法:
- 进行了一项具有前随机干预组件的多中心回顾性队列研究.
- 血清雌激素 (E2),葡萄糖代谢标志物 (禁食葡萄糖,HbA1c,CV%) 和护理指标 (伤口愈合,感染,坚持,住院) 进行了术后监测.
- 使用卡普兰-梅尔曲线和考克斯模型分析了生存结果 (无进展生存,总生存).
主要成果:
- 甲胺降低了化疗后19.3%的血清E2水平,并改善了血糖控制,禁食葡萄糖遵守率为83.3%,血糖CV%降低了38.2%.
- 在伤口愈合时间 (缩短3.3天),化疗坚持 (92.8%与73.6%) 和自我护理得分 (25.8%与7.2%) 中观察到显著改善.
- 机械洞察力表明,甲胺增强了免疫微环境调节,并减少了促炎细胞因子.
结论:
- 整合到结构化护理护理中,甲胺在雌激素控制,代谢稳定性和LABCT2DM患者的存活率方面显示出显著的益处.
- 这些发现支持梅特福林在同时患有癌症和代谢并发病症的患者的药物护理管理中的实用性.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
583
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
583
01:22Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K